Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from iX Biopharma Ltd. ( (SG:42C) ) is now available.
iX Biopharma Ltd. has announced its proposal to appoint BDO LLP as the new auditors for the financial year ending June 2025, following shareholder disapproval of PricewaterhouseCoopers LLP’s re-appointment. The Audit & Risk Committee recommended BDO after considering several proposals, ensuring alignment with regulatory frameworks and industry standards. BDO has consented to the appointment, pending shareholder approval, while PwC confirmed no professional objections to the transition. This change is expected to support the company’s audit operations without significant alterations in the audit scope.
More about iX Biopharma Ltd.
iX Biopharma Ltd. is a company incorporated in Singapore, operating within the biopharmaceutical industry. It focuses on developing and distributing pharmaceutical products and solutions, with a primary emphasis on leveraging its sublingual delivery technology to enhance drug efficacy and patient experience.
Average Trading Volume: 243,480
Technical Sentiment Consensus Rating: Buy
Current Market Cap: S$17.67M
See more insights into 42C stock on TipRanks’ Stock Analysis page.